Related references
Note: Only part of the references are listed.High-dose influenza vaccine favors acute plasmablast responses rather than long-term cellular responses
Jin Hyang Kim et al.
VACCINE (2016)
Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice
Karen K. Yam et al.
VACCINE (2016)
AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes
Corey P. Mallett et al.
VACCINE (2015)
Beyond adjuvants: Antagonizing inflammation to enhance vaccine immunity
Galit Alter et al.
VACCINE (2015)
AS03-adjuvanted, very-low-dose influenza vaccines induce distinctive immune responses compared to unadjuvanted high-dose vaccines in BALB/c mice
Karen K. Yam et al.
FRONTIERS IN IMMUNOLOGY (2015)
Heterologous Prime-Boost Vaccination Using an AS03(B)-Adjuvanted Influenza A(H5N1) Vaccine in Infants and Children < 3 Years of Age
Terry Nolan et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines
Julie Ann et al.
VACCINE (2014)
An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age
Airi Poder et al.
VACCINE (2014)
Unusual Patterns of IgG Avidity in Some Young Children following Two Doses of the Adjuvanted Pandemic H1N1 (2009) Influenza Virus Vaccine
Karen K. Yam et al.
CLINICAL AND VACCINE IMMUNOLOGY (2013)
An assessment of prime-boost vaccination schedules with AS03A-adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults
Paul Gillard et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2013)
Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months (vol 29, pg 6408, 2011)
George Risi et al.
VACCINE (2013)
Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial
William H. Yang et al.
VACCINE (2013)
Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine An open-label, randomized study in adults aged 18-60 years and older
Pierre Van Damme et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Effects of Different Adjuvants in the Context of Intramuscular and Intranasal Routes on Humoral and Cellular Immune Responses Induced by Detergent-Split A/H3N2 Influenza Vaccines in Mice
Mariana Baz et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 Adjuvant
Murdo Ferguson et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Safety and immunogenicity of a split-virion AS03A-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine in Taiwanese adults
Pan-Chyr Yang et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2012)
Randomized, Multicenter Trial of a Single Dose of AS03-adjuvanted or Unadjuvanted H1N1 2009 Pandemic Influenza Vaccine in Children 6 Months to <9 Years of Age
Joanne M. Langley et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2012)
Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older
Hideyuki Ikematsu et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine An open-label, randomized trial in Japanese children aged 6 months to 17 years
Akihiko Saitoh et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults
Hideyuki Ikematsu et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses
Philippe Moris et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2011)
Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A Phase III, Placebo-Controlled, Randomized Study
Joanne M. Langley et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial
Karl G. Nicholson et al.
LANCET INFECTIOUS DISEASES (2011)
Induction of Bordetella pertussis-specific immune memory by DTPa vaccines
Sandra Morel et al.
VACCINE (2011)
Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children
Vladimir Gilca et al.
VACCINE (2011)
Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity
Sandra Morel et al.
VACCINE (2011)
Vaccine Adjuvants: Putting Innate Immunity to Work
Robert L. Coffman et al.
IMMUNITY (2010)
Comparison of the Immune Responses Induced by Chimeric Alphavirus-Vectored and Formalin-Inactivated Alum-Precipitated Measles Vaccines in Mice
M. Jeff Bergen et al.
PLOS ONE (2010)
Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study
Isabel Leroux-Roels et al.
VACCINE (2010)
The thymus-independent immunity conferred by a pneumococcal polysaccharide is mediated by long-lived plasma cells
Morgan Taillardet et al.
BLOOD (2009)
Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data
Geert Leroux-Roels
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
The third dimension of ELISPOTs: Quantifying antibody secretion from individual plasma cells
Erin Bromage et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2009)
Modulation of Single-Cell IgG Secretion Frequency and Rates in Human Memory B Cells by CpG DNA, CD40L, IL-21, and Cell Division
Alicia D. Henn et al.
JOURNAL OF IMMUNOLOGY (2009)
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only
Sandra L. Giannini et al.
VACCINE (2006)
Maintenance of serological memory by polyclonal activation of human memory B cells
NL Bernasconi et al.
SCIENCE (2002)
Share Paper
